Investor Presentaiton slide image

Investor Presentaiton

Summary Global leader in Targeted Copper Theranostics (TCT) Extensive pipeline of TCTs based on 64Cu for diagnosis and 67Cu for therapy ■ TCTs address the current manufacturing and logistical limitations in the growth of radiopharmaceuticals ■ TCT are scalable, sustainable and dependable Broad and defensible IP portfolio of patent families across the SAR Technology platform, pipeline and products Pipeline includes large and orphan indications, with focus on the US for first approvals Well funded with $95.9M in cash Led by an experienced management team and Board with significant years of active involvement in the radiopharmaceutical industry Hot sector of the market with numerous recent acquisitions. CLARITY 2014 MEIE 64CU SAR-bisPSMA PET/CT in mCRPC 34
View entire presentation